Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.

Details

Ressource 1Download: 32713938_BIB_ED664BCFFB6F.pdf (626.12 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_ED664BCFFB6F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Journal
British journal of cancer
Author(s)
Middleton M.R., Hoeller C., Michielin O., Robert C., Caramella C., Öhrling K., Hauschild A.
ISSN
1532-1827 (Electronic)
ISSN-L
0007-0920
Publication state
Published
Issued date
09/2020
Peer-reviewed
Oui
Volume
123
Number
6
Pages
885-897
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The emergence of human intratumoural immunotherapy (HIT-IT) is a major step forward in the management of unresectable melanoma. The direct injection of treatments into melanoma lesions can cause cell lysis and induce a local immune response, and might be associated with a systemic immune response. Directly injecting immunotherapies into tumours achieves a high local concentration of immunostimulatory agent while minimising systemic exposure and, as such, HIT-IT agents are associated with lower toxicity than systemic immune checkpoint inhibitors (CPIs), enabling their potential use in combination with other therapies. Consequently, multiple HIT-IT agents, including oncolytic viruses, pattern-recognition receptor agonists, injected CPIs, cytokines and immune glycolipids, are under investigation. This review considers the current clinical development status of HIT-IT agents as monotherapy and in combination with systemic CPIs, and the practical aspects of administering and assessing the response to these agents. The future of HIT-IT probably lies in its use in combination with systemic CPIs; data from Phase 2 trials indicate a synergy between HIT-IT and CPIs. Data also suggest that the addition of HIT-IT to a CPI might generate responses in CPI-refractory tumours, thereby overcoming resistance and addressing a current unmet need in unresectable and metastatic melanoma for treatment options following progression after CPI treatment.
Pubmed
Web of science
Open Access
Yes
Create date
11/08/2020 11:22
Last modification date
15/01/2021 8:12
Usage data